Cargando…

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study

AIMS: IMPROVE™ is an open-label, multinational, non-randomised, 26-week observational study designed to evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in routine clinical practice. Here, we report data for patients switching to BIAsp 30 from human premixed insulin. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, S, Benroubi, M, Borzi, V, Gumprecht, J, Kawamori, R, Shaban, J, Shestakova, M, Wenying, Y, Valensi, P
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Diabetes & Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705824/ https://www.ncbi.nlm.nih.gov/pubmed/19210701 http://dx.doi.org/10.1111/j.1742-1241.2009.02012.x

Ejemplares similares

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)
por: Aravind, S. R., et al.
Publicado: (2022)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
por: Aravind, S. R., et al.
Publicado: (2022)

Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
por: Margaritidis, Charalampos, et al.
Publicado: (2021)

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings
por: Liebl, Andreas, et al.
Publicado: (2012)

Patient treatment satisfaction after switching to NovoMix(®) 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
por: Brod, Meryl, et al.
Publicado: (2010)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2013)

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)

Efficacy of a New Protocol of Premixed 70/30 Human Insulin in Haitian Youth with Diabetes
por: Jean-Baptiste, Eddy, et al.
Publicado: (2021)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus
por: Domeki, Nozomi, et al.
Publicado: (2014)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Efficacy and safety of patient‐directed titration of once‐daily pre‐dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP‐AKITA study
por: Narita, Takuma, et al.
Publicado: (2011)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Subject‐driven titration of biphasic insulin aspart 30 twice daily is non‐inferior to investigator‐driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open‐label, parallel‐group, multicenter trial
por: Yang, Wenying, et al.
Publicado: (2015)

Biphasic human insulin 30 thrice daily, is it reasonable?
por: Saadeh, Nesreen A., et al.
Publicado: (2020)

28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
por: Murthy, Sreenivasa, et al.
Publicado: (2021)

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
por: Gallwitz, Baptist, et al.
Publicado: (2011)

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A(1) chieve study
por: Bhattacharyya, Arpandev, et al.
Publicado: (2014)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
por: Franek, E., et al.
Publicado: (2015)

Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A(1)chieve® observational study
por: Yang, Wenying, et al.
Publicado: (2014)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes
por: Linjawi, Sultan, et al.
Publicado: (2017)

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study
por: Shanmugasundar, G., et al.
Publicado: (2012)

Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study
por: Song, Kee-Ho, et al.
Publicado: (2013)

Biphasic insulin aspart‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
por: Tsujino, Daisuke, et al.
Publicado: (2017)

A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes
por: Kapitza, Christoph, et al.
Publicado: (2020)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l9rh5s6nb3t6l80p9nnse3j30c